申请人:Hoffmann-La Roche Inc.
公开号:US05856517A1
公开(公告)日:1999-01-05
Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.1' are independently alkyl, aryl, alkenyl or alkynyl; R.sup.2 and R.sup.2' are independently hydrogen or alkyl; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently are ##STR2## CH.sub.2 OR.sup.10, CHO, CH.sub.2 NR.sup.11 R.sup.12, hydrogen, halogen, cyano, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, acylamino, aralkyloxy, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or alkylsulphonyl, provided that at least one of R.sup.4, R.sup.5, R.sup.6 or R.sup.7 is cyano, ##STR3## CH.sub.2 OR.sup.10, CH.sub.2 NR.sup.11 R.sup.12, or CHO ; R.sup.8 is alkyl, aralkyl or aryl; R.sup.10 is hydrogen, alkyl, aralkyl or aryl; R.sup.11 and R.sup.12 are independently hydrogen, alkyl, aryl, aralkyl or acyl; one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); as well as pharmaceutically acceptable prodrugs or salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiproliferative agents useful in the treatment of cancer.
化合物的公式为##STR1##其中R.sup.1和R.sup.1'分别是烷基,芳基,烯基或炔基; R.sup.2和R.sup.2'分别是氢或烷基; R.sup.4,R.sup.5,R.sup.6和R.sup.7各自独立地是##STR2## CH.sub.2 OR.sup.10,CHO,CH.sub.2 NR.sup.11 R.sup.12,氢,卤素,氰基,烷基,羟基,烷氧基,芳氧基,卤代烷基,硝基,氨基,酰胺基,芳基氧基,单烷基氨基,双烷基氨基,烷基硫基,烷基亚磺酰基或烷基磺酰基,前提是R.sup.4,R.sup.5,R.sup.6或R.sup.7中至少有一个是氰基,##STR3## CH.sub.2 OR.sup.10,CH.sub.2 NR.sup.11 R.sup.12或CHO; R.sup.8是烷基,芳基烷基或芳基; R.sup.10是氢,烷基,芳基烷基或芳基; R.sup.11和R.sup.12独立地是氢,烷基,芳基,芳基烷基或酰基; X和Y中的一个表示O,另一个表示O,S,(H,OH)或(H,H);以及公式I的酸性化合物的药物可接受的前药或与酸的公式I的碱性化合物的盐是抗增殖剂,可用于治疗癌症。